Small molecule agents for triple negative breast cancer: Current status and future prospects
Article in Translational Oncology (January 2024)
The most recent citing publications are shown below. View all 21 publications that cite this research output on Dimensions.
A second-generation eIF4A RNA helicase inhibitor exploits translational reprogramming as a vulnerability in triple-negative breast cancer
Article in Proceedings of the National Academy of Sciences of the United States of America (January 2024)
TRPML1 as a potential therapeutic target for triple-negative breast cancer: a review
Article in Frontiers in Oncology (December 2023)